Will Ultragenyx/Kyowa Hypophosphatemia Data Support Uptake?
Ultragenyx and partner Kyowa Hakko Kirin said burosumab (KRN23) met the primary endpoint regarding phosphate levels in a Phase III study that enrolled adult X-linked hypophosphatemia patients, but small effects on two out of three secondary endpoints could impact the product's use.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Commercial opportunity for Mepsevii is small, but launch paves way for company's second product burosumab, following on its heels.
The latest US drug development news and highlights from our Performance Tracker.